AVENUE THERAPEUTICS INC (ATXI) Financials

ATXI

FY2025 annual

Revenue $1.4M YoY not available

Net Income -$2.9M +75.0% YoY

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$1.8M +79.7% YoY

Market Cap $2.0M as of Sep 11, 2026

Price / Sales 1.4x on $1.4M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.5x on $569K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATXI SEC filings page.

AVENUE THERAPEUTICS INC (ATXI) reported $1.4M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATXI FY2025 2026-08-29

Avenue’s early revenue base is outweighed by operating costs, leaving financing-led cash support as the dominant business mechanic.

Cash conversion is less negative than reported earnings: FY2025 operating cash outflow was $1.8M versus a net loss of $2.9M, indicating noncash or working-capital effects softened the immediate cash impact. Financing provided $2.1M, exceeding operating cash outflow and making external funding—not operations—the source of net cash support.

Spending composition shifted materially: R&D fell from $6.1M in FY2023 to $1.0M in FY2025. Yet FY2025’s net margin was -207.2%, showing that the new revenue base had not absorbed the remaining cost structure.

Liabilities rose from $268K in FY2023 to $1.1M in FY2025, and all FY2025 liabilities were current, concentrating obligations in the near term. The reported liquidity comparison equaled 18.7 months of the latest annual operating outflow, a balance-to-outflow measure rather than a forecast.

Financial Health Signals

Financial health score not available

AVENUE THERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

AVENUE THERAPEUTICS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

AVENUE THERAPEUTICS INC reported a net loss of $2.9M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

AVENUE THERAPEUTICS INC generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Net Income

-$690K

YoY-306.0%

QoQ+0.7%

AVENUE THERAPEUTICS INC reported -$690K in net income in Q2 2026. This represents a decrease of 306.0% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

EBITDA

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$1.9M

YoY-41.6%

QoQ-19.7%

5Y CAGR+11.6%

10Y CAGR+50.8%

AVENUE THERAPEUTICS INC held $1.9M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+3.5%

QoQ0.0%

5Y CAGR-27.8%

AVENUE THERAPEUTICS INC had 3M shares outstanding in Q2 2026. This represents an increase of 3.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-121.3%

YoY-129.5pp

QoQ-63.3pp

AVENUE THERAPEUTICS INC's ROE was -121.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 129.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 63.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$247K

YoY+28.6%

QoQ+23.5%

AVENUE THERAPEUTICS INC invested $247K in research and development in Q2 2026. This represents an increase of 28.6% from the same quarter a year earlier. Against the prior quarter it is up 23.5%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ATXI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATXI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	$1.4M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.0M-84.4%	$6.6M+8.4%	$6.1M+127.2%	$2.7M+115.2%	$1.3M-56.2%	$2.9M-87.1%	$22.2M+25.4%	$17.7M+164.2%	$6.7M	N/A	$961K
SG&A Expenses	N/A	$3.7M-21.2%	$4.6M+11.0%	$4.2M-21.8%	$5.3M+115.2%	$2.5M+5.8%	$2.3M-23.6%	$3.1M-25.5%	$4.1M+13.8%	$3.6M	N/A	$842K
Operating Income	N/A	-$3.1M+72.7%	-$11.3M	N/A	-$8.0M-115.2%	-$3.7M+28.3%	-$5.2M+80.2%	-$26.3M-20.4%	-$21.8M-91.0%	-$11.4M	N/A	-$4.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$294K-30.0%	$420K+95.3%	$215K
Income Tax	N/A	$2K	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$2.9M+75.0%	-$11.7M	N/A	-$3.6M+4.8%	-$3.7M+27.6%	-$5.2M+80.1%	-$25.9M-20.2%	-$21.5M-75.8%	-$12.3M	N/A	-$5.2M
EPS (Basic)	N/A	-$0.93+94.1%	-$15.79+78.5%	-$73.48-4408.0%	-$1.63-640.9%	-$0.22+29.0%	-$0.31	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	N/A	N/A	N/A	N/A	-$0.22+29.0%	-$0.31	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	2M	1M-93.1%	17M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0-100.0%	N/A	N/A	$0	$1.4M	N/A	N/A	$0
R&D Expenses	$247K+28.6%	$200K-51.3%	N/A	$177K-92.4%	$192K-85.9%	$411K-82.8%	N/A	$2.3M+156.6%
SG&A Expenses	$460K-49.7%	$514K-65.6%	N/A	$547K-34.0%	$915K-37.4%	$1.5M+13.5%	N/A	$829K-28.6%
Operating Income	-$707K-338.0%	-$714K+62.5%	N/A	-$724K+77.1%	$297K+110.5%	-$1.9M+48.6%	N/A	-$3.2M-52.6%
Net Income	-$690K-306.0%	-$695K+62.5%	N/A	-$683K+77.8%	$335K+112.4%	-$1.9M+57.3%	N/A	-$3.1M-684.8%
EPS (Basic)	-$0.21-290.9%	-$0.21+66.1%	-$0.22-114.9%	-$0.21+89.1%	$0.11+101.7%	-$0.62+96.0%	$1.48+164.3%	-$1.92-139.5%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax, EPS (Diluted), Diluted Shares (Avg).

ATXI Balance Sheet

ATXI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$2.9M+9.7%	$2.7M+44.4%	$1.9M-73.0%	$6.8M+72.9%	$4.0M+22.0%	$3.2M-63.6%	$8.9M+97.0%	$4.5M-79.6%	$22.2M+11153.8%	$197K	N/A
Current Assets	N/A	N/A	N/A	N/A	$4.0M+22.0%	$3.2M	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$2.9M+10.1%	$2.6M+45.5%	$1.8M-73.4%	$6.7M+78.3%	$3.8M+20.1%	$3.1M-64.2%	$8.7M+227.4%	$2.7M-77.3%	$11.8M+5880.7%	$197K+1307.1%	$14K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$10.0M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.1M+979.2%	-$125K-146.6%	$268K-92.5%	$3.6M+603.1%	$509K-42.6%	$886K-58.1%	$2.1M-59.0%	$5.2M+84.8%	$2.8M-67.0%	$8.4M	N/A
Current Liabilities	$1.1M+34.7%	$816K	N/A	$3.6M+603.1%	$509K-42.6%	$886K-58.1%	$2.1M-59.0%	$5.2M+84.8%	$2.8M-56.5%	$6.4M	N/A
Non-Current Liabilities	$0+100.0%	-$941K	N/A	$0	$0	$0	$0	$0	$0-100.0%	$2.0M	N/A
Total Equity	$1.8M-34.5%	$2.8M+76.8%	$1.6M-59.5%	$3.9M+13.2%	$3.5M+46.3%	$2.4M-65.3%	$6.8M+1177.7%	-$631K-103.3%	$19.4M+335.0%	-$8.2M-60.6%	-$5.1M
Retained Earnings	-$105.5M-2.8%	-$102.6M-12.8%	-$90.9M-12.9%	-$80.6M-4.6%	-$77.0M-5.1%	-$73.3M-7.6%	-$68.1M-61.4%	-$42.2M-104.3%	-$20.7M-145.9%	-$8.4M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.0M-52.5%	$2.5M-31.3%	$2.9M+9.7%	$3.7M+41.9%	$4.2M-16.6%	$3.6M+8.6%	$2.7M+44.4%	$2.6M+422.9%
Cash & Equivalents	$1.9M-41.6%	$2.4M-31.0%	$2.9M+10.1%	$3.7M+42.8%	$3.3M-32.4%	$3.5M+9.6%	$2.6M+45.5%	$2.6M+1513.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.4M+1266.0%	$1.3M+1411.9%	$1.1M+979.2%	$168K+1020.0%	$103K-91.1%	$84K-82.3%	-$125K-146.6%	$15K-99.6%
Current Liabilities	$1.4M	$1.3M	$1.1M+34.7%	N/A	N/A	N/A	$816K	N/A
Non-Current Liabilities	$0	$0	$0+100.0%	N/A	N/A	N/A	-$941K	N/A
Total Equity	$569K-86.0%	$1.2M-65.9%	$1.8M-34.5%	$3.6M+36.3%	$4.1M-14.8%	$3.5M+23.8%	$2.8M+76.8%	$2.6M+171.5%
Retained Earnings	-$106.9M-2.7%	-$106.2M-1.7%	-$105.5M-2.8%	-$104.8M-3.7%	-$104.1M-6.3%	-$104.4M-9.6%	-$102.6M-12.8%	-$101.0M-10.3%

Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ATXI Cash Flow Statement

ATXI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$1.4M	-$1.8M+79.7%	-$9.0M	N/A	-$7.6M-102.6%	-$3.8M+18.7%	-$4.6M+82.4%	-$26.3M-44.2%	-$18.2M-167.8%	-$6.8M	N/A	-$895K
Stock-Based Compensation	N/A	$665K-46.2%	$1.2M+36.4%	$906K+39.6%	$649K+46.8%	$442K-37.7%	$710K-61.4%	$1.8M+19.6%	$1.5M+154.5%	$604K+2057.1%	$28K-3.4%	$29K
Investing Cash Flow	N/A	N/A	$0+100.0%	-$3.0M	$0	N/A	-$1.0M	$0-100.0%	$10.0M+200.0%	-$10.0M	$0+100.0%	-$3.0M
Financing Cash Flow	$0	$2.1M-78.7%	$9.8M+30.7%	$7.5M-28.6%	$10.5M+140.6%	$4.4M	$0-100.0%	$32.3M+3712.6%	-$895K-103.2%	$28.4M	N/A	$3.9M
Share Buybacks	N/A	N/A	N/A	$0-100.0%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$475K-169.9%	-$438K+63.1%	-$854K-11.8%	$383K+113.3%	-$176K+92.2%	-$1.2M+62.0%	-$764K+67.1%	-$2.9M-225.0%
Stock-Based Compensation	$61K-65.1%	$61K-67.0%	N/A	$163K-50.8%	$175K-8.9%	$185K-3.1%	N/A	$331K-41.0%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0+100.0%
Financing Cash Flow	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$2.1M-53.8%	$761K-80.7%	$567K+18.4%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

ATXI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATXI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Margin	-219.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-207.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-158.8%+257.8pp	-416.6%	N/A	-91.0%+17.1pp	-108.1%+110.3pp	-218.4%+162.6pp	-381.0%	N/A	-63.2%	N/A	N/A
Return on Assets	-99.3%+336.8pp	-436.1%	N/A	-51.9%+42.3pp	-94.2%+64.5pp	-158.7%+131.9pp	-290.6%+185.6pp	-476.2%-420.9pp	-55.3%	N/A	N/A
Current Ratio	N/A	N/A	N/A	N/A	7.78+4.1x	3.66	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.60	N/A	0.17-0.7x	0.92+0.8x	0.15-0.2x	0.38+0.1x	0.31	N/A	0.14	N/A	N/A
Asset Turnover	0.48+0.5x	0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	21.1%	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	23.9%	N/A	N/A	N/A
Return on Equity	-121.3%-129.5pp	-58.0%-5.2pp	N/A	-19.2%+98.7pp	8.3%+64.8pp	-52.8%+100.3pp	N/A	-117.9%
Return on Assets	-34.9%-43.0pp	-28.2%+23.4pp	N/A	-18.3%+98.8pp	8.1%+62.0pp	-51.5%+79.6pp	N/A	-117.2%-222.0pp
Debt-to-Equity	2.47+2.4x	1.06+1.0x	0.60	0.050.0x	0.03-0.2x	0.02-0.1x	N/A	0.01
Asset Turnover	0.00-0.3x	N/A	N/A	0.000.0x	0.34+0.3x	N/A	N/A	0.00

Not reported in any period shown, so not listed: Gross Margin, Current Ratio, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AVENUE THERAPEUTICS INC ATXI	FY2025	$1.4M	-$2.9M	N/A	$2.0M	—
MOSAIC IMMUNOENGINEERING CPMV	FY2025	N/A	N/A	N/A	$616K	—
NASCENT BIOTECH INC NBIO	FY2024	N/A	-$2.1M	N/A	$3.3M	—

Where AVENUE THERAPEUTICS INC Ranks

Frequently Asked Questions

What is AVENUE THERAPEUTICS INC's annual revenue?

AVENUE THERAPEUTICS INC (ATXI) reported $1.4M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is AVENUE THERAPEUTICS INC profitable?

No, AVENUE THERAPEUTICS INC (ATXI) reported a net income of -$2.9M in fiscal year 2025.

What is AVENUE THERAPEUTICS INC's return on equity (ROE)?

AVENUE THERAPEUTICS INC (ATXI) has a return on equity of -158.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is AVENUE THERAPEUTICS INC's operating cash flow?

AVENUE THERAPEUTICS INC (ATXI) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are AVENUE THERAPEUTICS INC's total assets?

AVENUE THERAPEUTICS INC (ATXI) had $2.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does AVENUE THERAPEUTICS INC spend on research and development?

AVENUE THERAPEUTICS INC (ATXI) invested $1.0M in research and development during fiscal year 2025.

How many shares does AVENUE THERAPEUTICS INC have outstanding?

AVENUE THERAPEUTICS INC (ATXI) had 3M shares outstanding as of fiscal year 2025.

What is AVENUE THERAPEUTICS INC's debt-to-equity ratio?

AVENUE THERAPEUTICS INC (ATXI) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AVENUE THERAPEUTICS INC's return on assets (ROA)?

AVENUE THERAPEUTICS INC (ATXI) had a return on assets of -99.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AVENUE THERAPEUTICS INC's P/E ratio?

AVENUE THERAPEUTICS INC (ATXI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.0M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AVENUE THERAPEUTICS INC's price-to-sales ratio?

AVENUE THERAPEUTICS INC (ATXI) trades at 1.4x sales, its market capitalization divided by revenue of $1.4M revenue, FY2025. The market capitalization is $2.0M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does AVENUE THERAPEUTICS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, AVENUE THERAPEUTICS INC (ATXI) held $2.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.8M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is AVENUE THERAPEUTICS INC's Piotroski F-Score?

AVENUE THERAPEUTICS INC (ATXI) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AVENUE THERAPEUTICS INC's earnings high quality?

AVENUE THERAPEUTICS INC (ATXI) reported a net loss of $2.9M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.